Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

Initial data on Amgen’s AMG 193 give some Tango investors a headache.

Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients. 

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.

Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.